Coagulation disorders in subjects undergoing pump-driven veno- venous ECCO2-R for severe acute hypercapnic respiratory failure - a single center experience

Standard

Harvard

APA

Vancouver

Bibtex

@article{89fa2e258dcf4e9580a24bf7b2a102da,
title = "Coagulation disorders in subjects undergoing pump-driven veno- venous ECCO2-R for severe acute hypercapnic respiratory failure - a single center experience",
abstract = "Introduction: Recent evidence suggests low-flow extracorporeal CO2 removal (ECCO2-R) systems as safe and promising adjunctive therapy to avoid endotracheal intubation and the related negative consequences in subjects with severe hypercapnic respiratory failure [1]. In high-flow extracorporeal membrane oxygenation systems heterogeneous coagulation disorders are a well-known complication. However, to date there is little evidence for the influence of pump-driven low-flow veno-venous ECCO2-R on the coagulation system.Objectives: This study is a retrospective analysis of four subjects developing coagulation disorders with bleeding complications while undergoing ECCO2-R.Methods: Four subjects treated with a pump-driven veno-venous ECCO2- R (system: iLA Activve{\textregistered}; membrane ventilator: Minilung{\textregistered}; Novalung GmbH, Talheim, Germany) for severe hypercapnic respiratory failure due to acute exacerbation of COPD were included in this study. Unfractionated heparin was used for anticoagulation with a target aPTT of 45-55 sec. Coagulation parameters i.e. hemoglobin, platelets, fibrinogen, antithrombin and D- DIMER were retrieved from the charts at treatment initiation and during the time range starting 72 hours before and ending at the clinical onset of the bleeding complication.Results: Mean application time of ECCO2-R was 196.5 h ( ± 77.4) with an average blood flow of 1.1 l/min ( ± 0.2). Bleeding events consisted of two pulmonary bleedings, one large soft tissue hematoma and one hemothorax. Coagulation parameters are depicted below in Table 1. ECCO2-R was removed in all subjects after onset of the bleeding complication resulting in stabilization of the coagulation state. Conclusions: Despite adequate anticoagulation subjects undergoing pump-driven veno-venous ECCO2-R developed coagulation disorders similar to disseminated intravascular coagulation with concomitant bleeding complications. The underlying mechanism remains to be clarified.",
author = "Ulrich Harler",
year = "2015",
language = "English",
journal = "INTENS CARE MED EXP",
issn = "2197-425X",
publisher = "Springer Science + Business Media",

}

RIS

TY - JOUR

T1 - Coagulation disorders in subjects undergoing pump-driven veno- venous ECCO2-R for severe acute hypercapnic respiratory failure - a single center experience

AU - Harler, Ulrich

PY - 2015

Y1 - 2015

N2 - Introduction: Recent evidence suggests low-flow extracorporeal CO2 removal (ECCO2-R) systems as safe and promising adjunctive therapy to avoid endotracheal intubation and the related negative consequences in subjects with severe hypercapnic respiratory failure [1]. In high-flow extracorporeal membrane oxygenation systems heterogeneous coagulation disorders are a well-known complication. However, to date there is little evidence for the influence of pump-driven low-flow veno-venous ECCO2-R on the coagulation system.Objectives: This study is a retrospective analysis of four subjects developing coagulation disorders with bleeding complications while undergoing ECCO2-R.Methods: Four subjects treated with a pump-driven veno-venous ECCO2- R (system: iLA Activve®; membrane ventilator: Minilung®; Novalung GmbH, Talheim, Germany) for severe hypercapnic respiratory failure due to acute exacerbation of COPD were included in this study. Unfractionated heparin was used for anticoagulation with a target aPTT of 45-55 sec. Coagulation parameters i.e. hemoglobin, platelets, fibrinogen, antithrombin and D- DIMER were retrieved from the charts at treatment initiation and during the time range starting 72 hours before and ending at the clinical onset of the bleeding complication.Results: Mean application time of ECCO2-R was 196.5 h ( ± 77.4) with an average blood flow of 1.1 l/min ( ± 0.2). Bleeding events consisted of two pulmonary bleedings, one large soft tissue hematoma and one hemothorax. Coagulation parameters are depicted below in Table 1. ECCO2-R was removed in all subjects after onset of the bleeding complication resulting in stabilization of the coagulation state. Conclusions: Despite adequate anticoagulation subjects undergoing pump-driven veno-venous ECCO2-R developed coagulation disorders similar to disseminated intravascular coagulation with concomitant bleeding complications. The underlying mechanism remains to be clarified.

AB - Introduction: Recent evidence suggests low-flow extracorporeal CO2 removal (ECCO2-R) systems as safe and promising adjunctive therapy to avoid endotracheal intubation and the related negative consequences in subjects with severe hypercapnic respiratory failure [1]. In high-flow extracorporeal membrane oxygenation systems heterogeneous coagulation disorders are a well-known complication. However, to date there is little evidence for the influence of pump-driven low-flow veno-venous ECCO2-R on the coagulation system.Objectives: This study is a retrospective analysis of four subjects developing coagulation disorders with bleeding complications while undergoing ECCO2-R.Methods: Four subjects treated with a pump-driven veno-venous ECCO2- R (system: iLA Activve®; membrane ventilator: Minilung®; Novalung GmbH, Talheim, Germany) for severe hypercapnic respiratory failure due to acute exacerbation of COPD were included in this study. Unfractionated heparin was used for anticoagulation with a target aPTT of 45-55 sec. Coagulation parameters i.e. hemoglobin, platelets, fibrinogen, antithrombin and D- DIMER were retrieved from the charts at treatment initiation and during the time range starting 72 hours before and ending at the clinical onset of the bleeding complication.Results: Mean application time of ECCO2-R was 196.5 h ( ± 77.4) with an average blood flow of 1.1 l/min ( ± 0.2). Bleeding events consisted of two pulmonary bleedings, one large soft tissue hematoma and one hemothorax. Coagulation parameters are depicted below in Table 1. ECCO2-R was removed in all subjects after onset of the bleeding complication resulting in stabilization of the coagulation state. Conclusions: Despite adequate anticoagulation subjects undergoing pump-driven veno-venous ECCO2-R developed coagulation disorders similar to disseminated intravascular coagulation with concomitant bleeding complications. The underlying mechanism remains to be clarified.

M3 - Other (editorial matter etc.)

JO - INTENS CARE MED EXP

JF - INTENS CARE MED EXP

SN - 2197-425X

ER -